- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02397239
Comparison of Cost-effectiveness of Continuation Maintenance Therapy With Six Cycles of Pemetrexed Versus Pemetrexed Until Disease Progression for Metastatic Non-squamous Non-small-cell Lung Cancer
Protocol title:
Comparison of cost-effectiveness of continuation maintenance therapy with six cycles of pemetrexed versus pemetrexed until disease progression for metastatic non-squamous non-small-cell lung cancer (NSCLC)
Study design:
An open-labelled, randomized, phase 2 trial
Indication:
Patients with stage IV non-squamous NSCLC, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and have received first-line or second-line chemotherapy with pemetrexed plus platinum for 4 cycles
Treatment:
Maintenance pemetrexed 500 mg/m2 every 3 weeks for six cycles versus until disease progression
Objectives:
Primary endpoint:
1. Progression-free survival in the intention-to-treat population
Secondary endpoints:
- Cost-effectiveness
- Overall survival
- Quality-of-life (QoL)
- Quality-adjusted progression-free survival (QA-PFS)
- Quality-adjusted life expectancy (QALE)
- Tumor response rate
- Adverse events
Planned sample size:
36 patients in each arm; total 72 patients
Total number of sites:
1 site
Duration of patient enrollment:
3 years
연구 개요
상태
정황
상세 설명
Inclusion criteria:
- Males and females ≥ 20 years of age
- ECOG performance status of 0-1
- Histologically or cytologically verified non-squamous NSCLC
- Stage IV disease, as defined by American Joint Committee on Cancer 7th edition staging, prior to first-line or second-line chemotherapy with pemetrexed plus platinum
- At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- Completion of 4 cycles of first-line or second-line chemotherapy with pemetrexed plus platinum and documented radiographic evidence of a complete or partial tumor response or stable disease by RECIST 1.1
Adequate organ function, including followings:
Bone marrow:
Absolute neutrophil count ≥ 1.5 x 103 /μL White blood cell ≥ 3.0 x 103 /μL Platelet count ≥ 75 x 103 /μL Hemoglobin ≥ 8.0 g/dL
Hepatic:
Total bilirubin ≤ 1.5 x upper normal limit (UNL) Aspartate aminotransferase (AST) ≤ 3.0 x UNL (≤ 5.0 x UNL if liver metastasis) Alanine aminotransferase (ALT) ≤ 3.0 x UNL (≤ 5.0 x UNL if liver metastasis)
Renal:
Estimated glomerular filtration rate ≥ 30 mL/min
- Estimated life expectancy of at least 6 months
- Ability to comply with study and follow-up procedures
- Signed informed consent document
Exclusion criteria:
- Squamous cell and/or mixed small-cell, non-small-cell histology
- Prior participation in any investigational drug study within 4 weeks
- Prior malignancy other than NSCLC, except those remain disease-free for ≥ 3 years after curative treatment, non-melanoma skin cancer or in situ cervical cancer
- Serious concomitant systemic disorders, such as acute or recent myocardial infarction (< 6 months before enrollment), congestive heart failure with New York Heart Association functional class II~IV, frequent exacerbations of chronic obstructive pulmonary disease (≥ 2 hospitalizations per year), or recent cerebrovascular disease (< 6 months before enrollment)
- Active uncontrolled infections or HIV infection
- Current or planned pregnancy, or breast feeding in women
- Symptomatic central nervous system metastasis unless the patient has completed successful local therapy and has been off corticosteroids for ≥ 4 weeks
- Concurrent administration of any other antitumor therapy including chemotherapy, target therapy, immunotherapy, and hormone therapy
- Psychiatric disorders that would compromise the patient's compliance or decision
Criteria for evaluation:
QoL:
QoL will be measured using the EuroQol 5-dimensional questionnaire (EQ-5D), World Health Organization Quality-of-Life, brief version (WHOQOL-BREF), European Organization for Research and Treatment of Cancer (EORTC) questionnaires.
Efficacy:
Tumor response rate will be determined by RECIST 1.1. Data of progression-free survival and overall survival will be collected for all subjects.
QA-PFS and QALE:
Investigators will adjust the progression-free survival by the utility values of QoL measured from the EQ-5D to obtain the QA-PFS. In addition, investigators will extrapolate the survival function to lifetime based on the survival ratios between patients and age- and sex-matched referents simulated from the life tables of Taiwan. After adjusting the lifetime survival by the utility values of QoL, the QALE will also be estimated using quality-adjusted life-year (QALY) as the unit.
Cost-effectiveness:
The monthly healthcare expenditures, which included National Health Insurance-reimbursed and out-of-pocket direct medical costs, will be obtained from the reimbursement database of National Cheng Kung University Hospital. These values were multiplied by the corresponding survival probabilities to calculate the lifetime costs or costs during the progression-free period. Hence, costs/life-year or costs/QALY can be obtained for comparison of cost-effectiveness.
Adverse events:
Safety parameters include laboratory adverse events (e.g., anemia, leukopenia, neutropenia, thrombocytopenia, creatinine, AST, ALT) and non-laboratory adverse events (e.g., fatigue, nausea, vomiting, mucositis/stomatitis, anorexia, diarrhea, constipation, infection, febrile neutropenia, pain, sensory neuropathy, rash, edema, watery eye). Common Terminology Criteria for Adverse Events (CTCAE) v4.0 will be used to grade toxicities.
연구 유형
등록 (예상)
연락처 및 위치
연구 장소
-
-
-
Tainan, 대만, 704
- 모병
- National Cheng Kung University Hospital
-
연락하다:
- Szu-Chun Yang, M.D.
- 전화번호: +886 972402279
- 이메일: yangszuchun@gmail.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Males and females ≥ 20 years of age
- ECOG performance status of 0-1
- Histologically or cytologically verified non-squamous NSCLC
- Stage IV disease, as defined by American Joint Committee on Cancer 7th edition staging, prior to first-line or second-line chemotherapy with pemetrexed plus platinum
- At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- Completion of 4 cycles of first-line or second-line chemotherapy with pemetrexed plus platinum and documented radiographic evidence of a complete or partial tumor response or stable disease by RECIST 1.1
Adequate organ function, including followings:
Bone marrow:
Absolute neutrophil count ≥ 1.5 x 103 /μL White blood cell ≥ 3.0 x 103 /μL Platelet count ≥ 75 x 103 /μL Hemoglobin ≥ 8.0 g/dL
Hepatic:
Total bilirubin ≤ 1.5 x upper normal limit (UNL) Aspartate aminotransferase (AST) ≤ 3.0 x UNL (≤ 5.0 x UNL if liver metastasis) Alanine aminotransferase (ALT) ≤ 3.0 x UNL (≤ 5.0 x UNL if liver metastasis)
Renal:
Estimated glomerular filtration rate ≥ 30 mL/min
- Estimated life expectancy of at least 6 months
- Ability to comply with study and follow-up procedures
- Signed informed consent document
Exclusion Criteria:
- Squamous cell and/or mixed small-cell, non-small-cell histology
- Prior participation in any investigational drug study within 4 weeks
- Prior malignancy other than NSCLC, except those remain disease-free for ≥ 3 years after curative treatment, non-melanoma skin cancer or in situ cervical cancer
- Serious concomitant systemic disorders, such as acute or recent myocardial infarction (< 6 months before enrollment), congestive heart failure with New York Heart Association functional class II~IV, frequent exacerbations of chronic obstructive pulmonary disease (≥ 2 hospitalizations per year), or recent cerebrovascular disease (< 6 months before enrollment)
- Active uncontrolled infections or HIV infection
- Current or planned pregnancy, or breast feeding in women
- Symptomatic central nervous system metastasis unless the patient has completed successful local therapy and has been off corticosteroids for ≥ 4 weeks
- Concurrent administration of any other antitumor therapy including chemotherapy, target therapy, immunotherapy, and hormone therapy
- Psychiatric disorders that would compromise the patient's compliance or decision
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: 보병대
- 시간 관점: 유망한
코호트 및 개입
그룹/코호트 |
---|
Six cycles
Maintenance pemetrexed 500 mg/m2 every 3 weeks for six cycles
|
Until disease progression
Maintenance pemetrexed 500 mg/m2 every 3 weeks until disease progression
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
무진행 생존
기간: 일년
|
일년
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
전반적인 생존
기간: 일년
|
일년
|
|
Cost-effectiveness: Cost/QA-PFS
기간: 2 years
|
Quality-adjusted progression-free survival (QA-PFS)
|
2 years
|
Quality-of-life (QoL) Questionnaire
기간: 1 year
|
1 year
|
|
Quality-adjusted progression-free survival (QA-PFS)
기간: 1 year
|
1 year
|
|
Quality-adjusted life expectancy (QALE)
기간: 1 year
|
1 year
|
|
종양 반응률
기간: 일년
|
일년
|
|
Number of Adverse events
기간: 1 year
|
1 year
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 완료
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- A-BR-103-062
- MOHW103-TD-B-111-06 (기타 보조금/기금 번호: The Ministry of Health and Welfare, Taiwan)
- MOHW103-TDU-B-211-113002 (The Ministry of Health and Welfare, Taiwan)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
비소세포폐암에 대한 임상 시험
-
Millennium Pharmaceuticals, Inc.완전한GCB(Non-Germinal B-cell-like) 미만성 거대 B-세포 림프종(DLBCL)미국